News from us and our partners

Tags

Topics

0 results

News
7 October, 2026
GenSight Biologics reports cash position as of Sept. 30, 2026
News
7 October, 2026
Mediar Therapeutics completes enrollment in Phase 2 WISPer Trial of MTX-463 in idiopathic pulmonary fibrosis (IPF)
News
7 October, 2026
Rezera announces positive RESOLVE-2 Phase 2 clinical trial results
News
6 October, 2026
TISSIUM® announces first U.S. patients treated with the ECLIPSIUM® System
News
5 October, 2026
AAVantgarde presents encouraging clinical data from AAVB-081 and preclinical data supporting AAVB-039 at EURetina 2026
News
1 October, 2026
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
News
30 September, 2026
Rezera announces phase 1 results for Trabzanoflast, which was generally well tolerated and demonstrated high central nervous system exposure (CNS)
News
29 September, 2026
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
News
28 September, 2026
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
News
28 September, 2026
Redx Announces Design of ROCKETEER Phase 2 Trial for RXC008 in Fibrostenotic Crohn’s Disease
News
28 September, 2026
Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies
News
24 September, 2026
Julier Medical appoints medtech industry veteran Will Martin as President and Chief Executive Officer
News
24 September, 2026
AFYREN announces its 2026 half-year financial results
News
24 September, 2026
Hemab Therapeutics strengthens Board of Directors with appointment of Keli Walbert
News
23 September, 2026
ProQR names Chris Hart as Chief Data and AI Officer; Thomas Wolf to join the Board of Directors as strategic AI advisor
News
23 September, 2026
Sensorion reports 2026 half-year results and provides corporate update

GenSight Biologics reports cash position as of Sept. 30, 2026

Mediar Therapeutics completes enrollment in Phase 2 WISPer Trial of MTX-463 in idiopathic pulmonary fibrosis (IPF)

Rezera announces positive RESOLVE-2 Phase 2 clinical trial results

TISSIUM® announces first U.S. patients treated with the ECLIPSIUM® System

AAVantgarde presents encouraging clinical data from AAVB-081 and preclinical data supporting AAVB-039 at EURetina 2026

Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD

Rezera announces phase 1 results for Trabzanoflast, which was generally well tolerated and demonstrated high central nervous system exposure (CNS)

GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Redx Announces Design of ROCKETEER Phase 2 Trial for RXC008 in Fibrostenotic Crohn’s Disease

Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies

Julier Medical appoints medtech industry veteran Will Martin as President and Chief Executive Officer

AFYREN announces its 2026 half-year financial results

Hemab Therapeutics strengthens Board of Directors with appointment of Keli Walbert

ProQR names Chris Hart as Chief Data and AI Officer; Thomas Wolf to join the Board of Directors as strategic AI advisor

Sensorion reports 2026 half-year results and provides corporate update